Simvastatin Attenuates Doxorubicin-Induced Inflammation in Human Cardiomyocytes
Roberta Vitale, Rosaria Margherita Rispoli, Maria Carmela Di Marcantonio, Barbara Pala, Stefania Marzocco, Gabriella Mincione, Ada Popolo · 2026
Read Simvastatin Attenuates Doxorubicin-Induced Inflammation in Human Cardiomyocytes by Roberta Vitale, Rosaria Margherita Rispoli, Maria Carmela Di Marcantonio, Barbara Pala, Stefania Marzocco, Gabriella Mincione, Ada Popolo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13204970.txt.
Description
Roberta Vitale and six co-authors wrote a 2026 study on whether a common cholesterol drug can shield heart cells from a cancer drug. Doxorubicin is a strong cancer drug whose use is capped by heart damage. That damage grows from oxidative stress and inflammation, driven by two linked switches in the cell. Simvastatin, a statin, calms those same paths.
The team pre-treated human heart muscle cells with simvastatin, then exposed them to doxorubicin for 20 hours. They measured enzymes and signals tied to inflammation, including nitric oxide output and three interleukins plus TNF-alpha. Flow analysis tracked related proteins, and gene tests checked one enzyme's expression. The design tests a cheap, familiar drug as a heart guard during cancer care. Results bear on cardio-oncology practice.
Catalog record
| CREATOR | Roberta Vitale, Rosaria Margherita Rispoli, Maria Carmela Di Marcantonio, Barbara Pala, Stefania Marzocco, Gabriella Mincione, Ada Popolo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |